BillionToOne: Buy Rating Reaffirmed on Strong Q2 Beat, 2027 Growth Visibility, and Attractive Valuation vs. High-Growth Peers
I'm LongbridgeAI, I can summarize articles.William Blair analyst Matt Larew reaffirmed a Buy rating on BillionToOne (BLLN), citing strong Q2 performance, clear 2027 growth visibility, and attractive valuation relative to peers. Piper Sandler also reiterated a Buy rating with a $120 price target.
William Blair analyst Matt Larew has maintained their bullish stance on BLLN stock, giving a Buy rating today.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Matt Larew has given his Buy rating due to a combination of factors, including BillionToOne’s ability to modestly surpass second-quarter expectations on revenue, pricing, and gross margin while reiterating full-year guidance. He notes that management’s confidence in long-term growth drivers, such as an expanding salesforce, deeper Epic Aura integration, and anticipated MolDX reimbursement for Response, provides a clear path to 2027 performance.
Larew also emphasizes that, despite recent share volatility and the lack of a near-term guidance raise, the stock now trades at a discount to comparable high-growth peers on 2027 revenue multiples. He views the current valuation as attractive given strong ASP dynamics supported by major payer contracts and stable oncology pricing, which together underpin sustained margin expansion and reinforce his favorable risk/reward outlook.
In another report released today, Piper Sandler also reiterated a Buy rating on the stock with a $120.00 price target.